Key statistics
As of last trade, Brainstorm Cell Therapeutics Inc (BCLI:NAQ) traded at 1.21, 15.24% above the 52 week low of 1.05 set on Nov 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.22 |
---|---|
High | 1.26 |
Low | 1.21 |
Bid | 1.21 |
Offer | 1.23 |
Previous close | 1.24 |
Average volume | 131.08k |
---|---|
Shares outstanding | 5.32m |
Free float | 4.84m |
P/E (TTM) | -- |
Market cap | 6.59m USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 17:13 GMT.
More ▼
- BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
- BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
- BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
- BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
More ▼